🇺🇸 FDA
Pipeline program

TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

IRST204.09

Phase 2 small_molecule active

Quick answer

TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX for Acute myeloid leukemia is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).

Program details

Company
Istituto Gentili S.r.l.
Indication
Acute myeloid leukemia
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials